Chemokine-mediated recruitment of inflammatory and smooth muscle cells in transplant-associated arteriosclerosis

Current Opinion in Organ Transplantation

Volumn 8, Issue 1, 2003, Pages 55-63

  Shimizu, Koichi ^a   Mitchell, Richard N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0842338982     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/00075200-200303000-00011     Document Type: Review

References (94)

1. Libby P, Salomon R, Payne D, et al.: Functions of vascular wall cells related to the development of transplant-associated coronary arteriosclerosis. Transplant Proc 1989, 21:3677-3684.
2. Libby P, Pober J: Chronic rejection. Immunity 2001, 14:387-397.
3. Libby P, Tanaka H: The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Clin Transplant 1994, 8:327-332.
4. Hillebrands J, Klatter F, van den Hurk BM, et al.: Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. J Clin Invest 2001, 107:1411-1422.
5. Li J, Han X, Jiang J, et al.: Vascular smooth muscle cells of recipient origin mediate intimal expansion after aortic allotransplantation in mice. Am J Pathol 2001, 158:1943-1947.
6. Saiura A, Sata M, Hirata Y, et al.: Circulating smooth muscle progenitor cells contribute to atherosclerosis. Nature Med 2001, 7:382-383.
7. Shimizu K, Sugiyama S, Aikawa M, et al.: Host bone-marrow cells are a source of donor intimal smooth muscle-like cells in murine aortic transplant arteriopathy. Circulation 2000, 102:II-221, II-V.
8. Shimizu K, Sugiyama S, Aikawa M, et al.: Host bone-marrow cells are a source of donor intimal smooth muscle-like cells in murine aortic transplant arteriopathy. Nature Med 2001, 7:738-741.
9. Grimm P, Nickerson P, Jeffery J, et al.: Neointimal and tubulointerstitial infiltration by recipient mesencymal cells in chronic renal-allograft rejection. N Eng J Med 2001, 345:93-97.
10. Costanzo M, Naftel D, Pritzker M, et al.: Heart transplant coronary artery disease detected by coronary angiography: A multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998, 17:744-753.
11. Hosenpud J, Bennett L, Keck B, et al.: The Registry of the International Society for Heart and lung transplantation: Fifteenth official report-1998. J Heart Lung Transplant 1998, 17:656-668.
12. Schoen F, Libby P: Cardiac transplant graft arteriosclerosis. Trends Cardiovasc Med 1991, 1:216-223.
13. Hauptman P, Nakagawa T, Tanaka H, et al.: Acute rejection: Culprit or coincidence in the pathogenesis of cardiac graft vascular disease? J Heart Lung Transplant 1995, 14:S173-S180.
14. Geerling R, DeBruin R, Scheringa M, et al.: Suppression of acute rejection prevents graft arteriosclerosis after allogeneic aorta transplantation in the rat. Transplantation 1994, 58:1258-1263.
15. Nagano H, Libby P, Taylor M, et al.: Coronary arteriosclerosis after T-cellmediated injury in transplanted mouse hearts. Role of Interferon-g. Am J Pathol 1998, 152:1187-1197.
16. Nakagawa T, Sukhova G, Rabkin E, et al.: Acute rejection accelerates graft coronary disease in transplanted rabbit hearts. Circulation 1995, 92:987-993.
17. Biedermann B, Pober J: Human endothelial cells induce and regulate cytolytic T cell differentiation. J Immunol 1998, 161:4679-4687.
18. Biedermann B, Pober J: Human vascular endothelial cells favor clonal expansion of unusual alloreactive CTL. J Immunol 1999, 162:7022-7030.
19. Hasegawa S, Becker G, Nagano H, et al.: Pattern of graft-and host-specific MHC class II expression in long-term murine cardiac allografts. Origin of inflammatory and vascular wall cells. Am J Pathol 1998, 153:1-11.
20. Hullett D, Geraghty J, Stoltenberg R, et al.: The impact of acute rejection on the development of intimal hyperplasia associated with chronic rejection. Transplantation 1996, 62:1842-1846.
21. Izutani H, Miyagawa S, Shirakura R, et al.: Evidence that graft coronary arteriosclerosis begins in the early phase after transplantation and progresses without chronic immunoreaction. Transplantation 1995, 60:1073-1079.
22. Tullius S, Hancock W, Heeman U, et al.: Reversibility of chronic renal allograft rejection: Critical effect of time after transplantation suggests both host immune-dependent and-independent phases of progressive injury. Transplantation 1994, 58:93-99.
23. Tilney N, Guttmann R: Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997, 64:945-947.
24. Hancock W, Buelow R, Sayegh M, et al.: Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nature Med 1998, 4:1392-1396.
25. Russell P, Chase C, Winn H, et al.: Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994, 152: 5135-5141.
26. Shi C, Lee W, He Q, et al.: Immunologic basis of transplant associated arteriosclerosis. Proc Natl Acad Sci USA 1996, 93:4051-4056.
27. Everett J, Hershberger R, Norman D, et al.: Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant 1992, 11:S133-S137.
28. Loebe M, Schuler S, Zais O, et al.: Role of cytomegalovirus infection in the development of coronary artery disease in the transplanted heart. J Heart Lung Transplant 1990, 9:707-711.
29. Nagano H, Nadeau K, Kusaka M, et al.: Infection-associated macrophage activation accelerates chronic renal allograft rejection in rats. Transplantation 1997, 64:1602-1605.
30. Farrar M, Schreiber R: The molecular cell biology of interferon-gamma and its receptor. Ann Rev Immunol 1993, 11:571-611.
31. Postlethwaite A: Role of T cells and cytokines in effecting fibrosis. Int Rev Immunol 1995, 12:247-258.
32. Roberts A, Sporn M: Physiologic actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993, 8:1-9.
33. Fabry Z, Waldschmidt M, Moore S, et al.: Antigen presentation by brain microvessel smooth muscle and endothelium. J Neuroimmunol 1990, 28:63-71.
34. Rossi D, Zlotnick A: The biology of chemokines and their receptors. Ann Rev Immunol 2000, 18:217-242.
35. Ward S, Bacon K, Westwick J: Chemokines and T lymphocytes: More than an attraction. Immunity 1998, 9:1-11.
36. Nagano H, Mitchell R, Taylor M, et al.: Interferon-g deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. J Clin Invest 1997, 100:550-557.
37. Hansson G: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890.
38. Laurat E, Poirier B, Tupin E, et al.: In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2001, 104:197-202.
39. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol 2001, 88:10K-15K.
40. Hansson G, Jonasson L, Holm J, et al.: Gamma interferon regulates vascular smooth muscle proliferation and Ia expression in vivo and in vitro. Circ Res 1988, 63:712-719.
41. Luster A: Chemokines: Chemotactic cytokines that mediate inflammation. N Eng J Med 1998, 338:436-445.
42. Nelson P, Krensky A: Chemokines, chemokine receptors, and allograft rejection. Immunity 2001, 14:377-386.
43. Zlotnik A, Yoshie O: Chemokines: a new classification system and their role in immunity. Immunity 2000, 12:121-127.
44. Colvin B, Thomson A: Chemokines, their receptors and transplant outcome. Transplantation 2002, 74:149-155.
45. El-Sawy T, Fahmy N, Fairchild R: Chemokines: Directing leukocyte traffic into allografts. Curr Opin Immunol 2002, 14:562-568.
46. Nelson P, Krensky A: Chemokines and allograft rejection: Narrowing the list of suspects. Transplantation 2001, 72:1195-1197.
47. Morita K, Miura M, Paolone D, et al.: Early chemokine cascades in murine cardiac grafts regulate T cell recruitment and progression of acute allograft rejection. J Immunol 2001, 167:2979-2984.
48. Cines DB, Pollak ES, Buck CA, et al.: Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998, 91:3527-3561.
49. Luscinskas FW, Gimbrone MA, Jr.: Endothelial-dependent mechanisms in chronic inflammatory leukocyte recruitment. Annu Rev Med 1996, 47:413-421.
50. Pattison J, Nelson PJ, Huie P, et al.: RANTES chemokine expression in cellmediated transplant rejection of the kidney. Lancet 1994, 343:209-211.
51. Marx N, Mach F, Sauty A, et al.: Peroxisome proliferator-activated receptorgamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. J Immunol 2000, 164:6503-6508.
52. Mach F, Sauty A, Iarossi A, et al.: Differential expression of three T lymphocyte- activating CXC chemokines by human atheroma-associated cells. J Clin Invest 1999, 104:1041-1050.
53. Melter M, Exeni A, Reinders M, et al.: Expression of the chemokine receptor CXCR3 and its ligand IP-10 during human cardiac allograft rejection. Circulation 2001, 104:2558-2564.
54. Zhao D, Hu Y, Miller G, et al.: Differential expression of the IFN-gammainducible CXCR3-binding chemokines, IFN-inducible protein 10, monokine induced by IFN, and IFN-inducible T cell alpha chemoattractant in human cardiac allografts: Association with cardiac allograft vasculopathy and acute rejection. J Immunol 2002, 169:1556-1560.
55. Greaves DR, Gordon S: Immunity, atherosclerosis and cardiovascular disease. Trends Immunol 2001, 22:180-181.
56. Robinson L, Nataraj C, Thomas D, et al.: A role for fractalkine and its receptor (CX(3)CR1) in cardiac allograft rejection. J Immunol 2000, 165:6067-6072.
57. Rollins B: Chemokines. Blood 1997, 90:909-928.
58. Nelken N, Coughlin S, Gordon D, et al.: Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991, 88:1121-1127.
59. Yla-Herttuala S, Lipton B, Rosenfeld M, et al.: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991, 88:5252-5256.
60. Combadiere C, Ahuja S, VanDamme J, et al.: Monocyte chemoattractant protein-3 is a functional ligand for CC chemokine recptors 1 and 2B. J Biol Chem 1995, 270:29671-29675.
61. Sarafi M, Garcia-Zepeda E, MacLean J, et al.: Murine monocyte chemoattractant protein (MCP)-5: A novel CC chemokine that is a structural and functional homologue of human MCP-1. J Exp Med 1997, 185:99-109.
62. von Hundelshausen P, Weber K, Huo Y, et al.: RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation 2001, 103:1772-1777.
63. Schober A, Manka D, von Hundelshausen P, et al.: Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury. Circulation 2002, 106:1523-1529.
64. Yun J, Fischbein M, Laks H, et al.: Rantes production during development of cardiac allograft vasculopathy. Transplantation 2001, 71:1649-1656.
65. Grone HJ, Weber C, Weber KS, et al.: Met-RANTES reduces vascular and tubular damage during acute renal transplant rejection: blocking monocyte arrest and recruitment. Faseb J 1999, 13:1371-1383.
66. Horuk R, Shurey S, Ng H, et al.: CCR1-specific non-peptide antagonist: Efficacy in a rabbit allograft rejection model. Immunol Lett 2001, 76:193-201.
67. Horuk R, Clayberger C, Krensky A, et al.: A non-peptide functional antagonist of the CCR1 chemokine receptor is effective in rat heart transplant rejection. J Biol Chem 2001, 276:4199-4204.
68. Song E, Zou H, Yao Y, et al.: Early application of Met-RANTES ameliorates chronic allograft nephropathy. Kidney Int 2002, 61:676-685.
69. Gao W, Topham P, King J, et al.: Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000, 105:35-44.
70. Gao W, Faia KL, Csizmadia V, et al.: Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001, 72:1199-1205.
71. Miura M, Morita K, Kobayashi H, et al.: Monokine induced by IFN-gamma is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol 2001, 167:3494-3504.
72. Hancock WW, Gao W, Csizmadia V, et al.: Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 2001, 193:975-980.
73. Yun J, Fischbein M, Whiting M, et al.: The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am J Pathol 2002, 161:1307-1313.
74. Kobayashi H, Novick A, Toma H, et al.: Chronic antagonism of Mig inhibits cellular infiltration and promotes survival of class II MHC disparate skin allografts. Transplantation 2002, 74:387-395.
75. Hancock WW, Lu B, Gao W, et al.: Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med 2000, 192:1515-1520.
76. Haskell CA, Hancock WW, Salant DJ, et al.: Targeted deletion of CX(3)CR1 reveals a role for fractalkine in cardiac allograft rejection. J Clin Invest 2001, 108:679-688.
77. Boring L, Gosling J, Chensue S, et al.: Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in CCR2 knockout mice. J Clin Invest 1997, 100:2552-2561.
78. Gu L, Rutledge B, Fiorillo J, et al.: In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 1997, 62:577-580.
79. Aiello R, Bourassa P, Lindsey S, et al.: Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Aretriosler Thromb Vasc Biol 1999, 19:1518-1525.
80. Gosling J, Slaymaker S, Gu L, et al.: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest 1999, 103:773-778.
81. Koga S, Auerbach M, Engeman T, et al.: T cell infiltration into class II MHCdisparate allografts and acute rejection is dependent on the IFN-gammainduced chemokine Mig J Immunol 1999, 163:4878-4885.
82. Asahara T, Murohara T, Sullivan A, et al.: Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
83. Lin Y, Weisdorf D, Solovey A, et al.: Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000, 105:71-77.
84. Hillebrands J, Klatter F, Dijk Wv, et al.: Bone marrow does not contribute substantially to endothelial-cell replacement in transplant arteriosclerosis. Nat Med 2002, 8:194-195.
85. Campbell J, Efendy J, Campbell G: Novel vascular graft grown within recipient's own peritoneal cavity. Circ Res 1999, 85:1173-1178.
86. Plissonier D, Nochy D, Poncet P, et al.: Sequential immunologic targeting of chronic experimental arterial allograft. Transplantation 1995, 60:414-424.
87. Kennedy L, Weissman I: Dual origin of intimal cells in cardiac-allograft arteriosclerosis. N Engl J Med 1971, 285:884-887.
88. Gibbons G, Dzau V: Molecular therapies for vascular diseases. Science 1996, 272:689-693.
89. Mann M, Gibbons G, Kernoff R, et al.: Genetic engineering of vein grafts resistant to atherosclerosis. Proc. Natl Acad Sci USA 1995, 92:4502-4506.
90. Pittenger M, Mackay A, Beck S, et al.: Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
91. Schecter A, Calderon T, Berman A, et al.: Human smooth muscle cells possess functional CCR5. J Biol Chem 2000, 275:5466-5471.
92. Watanabe T, Pakala P, Katagiri T, et al.: Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. J Vasc Res 2001, 38:341-349.
93. Shimizu K, Aikawa M, Takayama K, et al.: Cerivastatin has immunomodulatory effects on donor endothelial cells and host inflammatory cells and attenuates allograft arteriopathy. Circulation 2001, 104:II212-II213.
94. Hayes I, Jordan N, Towers S, et al.: Human vascular smooth muscle cells express receptors for CC chemokines. Arterioscler Thromb Vasc Biol 1998, 18:397-403.